Overview

This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the incidence of adverse drug reactions.

Eligibility

Inclusion Criteria:

1. Age 18-65 years;
2. Positive H. pylori status confirmed by 13C-urea breath test and no prior history of eradication therapy;
3. Voluntary participation and provision of written informed consent

Exclusion Criteria:

1. Allergy to any study medication (e.g., minocycline, keverprazan, amoxicillin);
2. Confirmed active peptic ulcer disease;
3. Prior history of H. pylori eradication treatment;
4. Use of antibiotics or bismuth agents within 4 weeks before treatment initiation, or use of proton pump inhibitors within 2 weeks;
5. Current use of corticosteroids, nonsteroidal anti-inflammatory drugs, or anticoagulants;
6. History of esophageal or gastric surgery;
7. Pregnancy or lactation;
8. Severe comorbidities, including hepatic, cardiovascular, pulmonary, or renal disease;
9. Alcohol abuse;
10. Gastric mucosa-associated lymphoid tissue lymphoma, malignant tumors, peptic ulcer disease, or bronchial asthma;
11. Concurrent use of specific medications: atazanavir or rilpivirine, tricyclic antidepressants, levodopa, acetaminophen, guaifenesin/dextromethorphan, monoamine oxidase inhibitors, tramadol, or similar agents.